

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Evidence generation plan

# Digitally enabled therapy for chronic tic disorders and Tourette syndrome: ORBIT

October 2024

## 1 Purpose of this document

[NICE's assessment of digitally enabled therapy for chronic tic disorders and Tourette syndrome](#) recommends that more evidence is generated while the Online Remote Behavioural Intervention for Tics (ORBIT) technology is being used in the NHS. A separate evidence generation plan has been produced for Neupulse, which is the other technology that was assessed and is not covered in this plan.

This plan outlines the evidence gaps and what real-world data needs to be collected for a NICE review of the technology again in the future. It is not a study protocol but suggests an approach to generating the information needed to address the evidence gaps. For assessing comparative treatment effects, well-conducted randomised controlled trials are the preferred source of evidence if these are able to address the research gap.

The company is responsible for ensuring that data collection and analysis takes place.

Guidance on commissioning and procurement of the technology will be provided by NHS England, who are developing a digital health technology policy framework to further outline commissioning pathways.

NICE will withdraw the guidance if the company does not meet the conditions in [section 4 on monitoring](#).

After the end of the evidence generation period (about 3 years), the company should submit the evidence to NICE in a form that can be used for decision making. NICE

will review all the evidence and assess whether the technology can be routinely adopted in the NHS.

## **2 Evidence gaps**

This section describes the evidence gaps, why they need to be addressed and their relative importance for future committee decision making.

The committee will not be able to make a positive recommendation without the essential evidence gaps (see [section 2.1](#)) being addressed. The company can strengthen the evidence base by also addressing as many other evidence gaps (see [section 2.2](#)) as possible. This will help the committee to make a recommendation by ensuring it has a better understanding of the patient or healthcare system benefits of the technology.

### **2.1 Essential evidence for future committee decision making**

#### **Impact of ORBIT on health-related quality of life**

The impact of the Online Remote Behavioural Intervention for Tics (ORBIT) technology on people's daily lives is uncertain. Information about the impact that the technology has on people's symptoms should be recorded using the Yale Global Tic Severity Scale, and quality-of-life data should be collected using an appropriate measure. Qualitative data should also be collected from the child or young person, and their parents or carers. This should include the impact on daily life, for example on self-esteem, social interactions and school or work attendance and performance.

#### **Longer-term data on the clinical impact of ORBIT**

Further information about the long-term impact of ORBIT is needed to support health-economic modelling and reduce uncertainty in projections to distant time horizons. To supplement existing data, outcomes should be collected at a minimum of 3 and 6 months after the intervention and ideally up to 24 months.

#### **Resource use**

More information on how using the technology would affect resource use in the NHS, during and after implementation, is needed to help the committee understand the

technology's cost effectiveness. Resource estimates should include the impact of the technology on services, for example those provided by local specialist clinics (including 'e-coach' time) and carers. This could free up resources that could be used to increase access to treatment or reduce waiting times.

## **2.2 Evidence that further supports committee decision making**

### **Clinical and cost effectiveness in different subgroups**

There is limited evidence for subgroups of children and young people with diagnosed comorbidities, including:

- attention deficit hyperactivity disorder
- obsessive-compulsive disorder
- autism spectrum disorder
- mood disorders and
- anxiety.

More information is also needed on the efficacy of ORBIT in people who have severe tic disorders, and in people from different ethnic backgrounds. There is no evidence for ORBIT in adults. Evidence on the use of ORBIT in adults would support future assessments on the impact of the technology in this population

## **3 Approach to evidence generation**

### **3.1 Evidence gaps and ongoing studies**

The external assessment group (EAG) did not identify any ongoing studies that may address the evidence gaps. The committee was made aware of an ongoing Online Remote Behavioural Intervention for Tics (ORBIT) study.

Table 1 summarises the evidence gaps. Information about evidence status is derived from the EAG's report; evidence that does not meet the scope and inclusion criteria is not included. The table shows the evidence available to the committee when the guidance was published.

**Table 1 Evidence gaps and ongoing studies**

| <b>Evidence gap</b>   | <b>ORBIT</b>                      |
|---|-----------------------------------|
| Impact of ORBIT on people's symptoms and health-related quality of life | Limited evidence<br>Ongoing study |
| Longer-term data on the clinical impact of ORBIT                        | Limited evidence<br>Ongoing study |
| Resource use  | Limited evidence<br>Ongoing study |
| Clinical and cost effectiveness in different subgroups                  | Limited evidence<br>Ongoing study |

### **3.2 Data sources**

Data could be collected using a combination of primary data collection, suitable real-world data sources, and data collected through the technology itself (for example, engagement data).

[NICE's real-world evidence framework](#) provides detailed guidance on assessing the suitability of a real-world data source to answer a specific research question.

[The NHS England Secure Data Environment \(SDE\)](#) service could potentially support this research. This platform provides access to high-standard NHS health and social care data that can be used for research and analysis. There are also sub-national SDEs that are designed to be agile and potentially modified to suit the needs of new projects. SDEs are data storage and access platforms that bring together many sources of data, such as from primary and secondary care, to enable research and analysis. They could be used to collect data to address the evidence gaps.

The [NHS Digital's Improving Access to Psychological Therapies data set \(IAPT\)](#) and [Mental Health Services Data Set \(MHSD\)](#) are real-world data sets that could potentially provide information about the impact that tic disorders have on mental health.

Some unreported data may be obtained from the UK ORBIT randomised controlled trial, such as further data on tic severity.

The quality and coverage of real-world data collections are of key importance when used in generating evidence. Active monitoring and follow up through a central

coordinating point is an effective and viable approach to ensuring good-quality data with broad coverage.

### **3.3 Evidence collection plan**

The suggested approach to addressing the evidence gaps for ORBIT is using mixed-methods. Quantitative data can be collected through a self-controlled study and qualitative information through interviews or surveys of people who have used the technology.

In a self-controlled study, each participant is compared with themselves at different time points. In this study those time points should be at baseline, 3 and 6 months. Further follow up to 24 months would be ideal.

The study should enrol a representative population; that is, people who would be offered standard care, including behavioural therapy, without digital technologies. This may include face-to-face appointments and monitoring. Eligibility for inclusion, and the point of starting follow up should be clearly defined and consistent during the study, to minimise selection bias.

Data should be collected from the point at which a person would become eligible for standard care. The study should also capture information on people who were eligible but chose not to use the technology or could not access it. Ideally, the studies should be run across multiple centres, aiming to recruit centres that represent the variety of care pathways in the NHS.

Incomplete records and potentially demographically imbalanced selection can lead to bias if unaccounted for. Data collection should follow a predefined protocol and quality assurance processes should be put in place to ensure the integrity and consistency of data collection. See [NICE's real-world evidence framework](#), which provides guidance on the planning, conduct, and reporting of real-world evidence studies.

## 3.4 Data to be collected

### Study criteria

- At recruitment, eligibility criteria for suitability of using the digital technology and inclusion in the real-world study should be reported, and include:
  - a clinical diagnosis of tic disorder or Tourette’s syndrome
  - position of the technology in the clinical pathway
  - the point that follow up starts.

### Baseline information and patient outcomes

- Information about individual characteristics at baseline, for example, sex, age, ethnicity, socioeconomic status, clinical diagnosis (and date of diagnosis), details of any comorbidities and treatments. Other important covariates should be chosen with input from clinical specialists to support subgroup analysis.
- Changes in tic severity using the Yale Global Tic Severity Rating Scale total score at baseline and over follow up (for a minimum of 3 and 6 months).
- Changes in patient quality of life using the Gilles de la Tourette Syndrome-Quality of Life Scale at baseline and over follow up (for a minimum of 3 months).
- Qualitative information about the impact of ORBIT on daily life, ideally including self-esteem, social interactions and school or work attendance and performance.
- Information on healthcare resource use and exacerbation-related hospitalisation costs related to tic disorders and Tourette syndrome. This should include emergency department visits, hospital admissions, length of stay, and GP visits. Changes in a person’s medication and any referrals should be captured within ORBIT’s escalation processes.

### Implementation

- Costs of digital technologies for supporting treatment of tic disorders and Tourette syndrome, including licence fees, healthcare professional staff time and training costs to support the service and costs of integration with NHS systems
- Access and uptake, including the number and proportion of eligible people who were able to, or accepted an offer to, access the technology, and reasons for refusal

- Engagement (including number of chapters completed and time to complete them, and ideally any revisits to the platform after the initial intervention) and drop-out information, including reasons for stopping.

### **Safety monitoring outcomes**

- Any adverse events arising from using digital technologies to support treatment of tic disorders and Tourette syndrome.

Data collection should follow a predefined protocol and quality assurance processes should be put in place to ensure the integrity and consistency of data collection. See [NICE's real-world evidence framework](#), which provides guidance on the planning, conduct, and reporting of real-world evidence studies.

### **3.5 Evidence generation period**

The evidence generation period should be 2 years. This will be enough time to implement the evidence generation study, collect the necessary information and analyse the collected data.

## **4 Monitoring**

The company must contact NICE:

- within 6 months of publication of this plan to confirm agreements are in place to generate the evidence
- annually to confirm that the data is being collected and analysed as planned.

The company should tell NICE, as soon as possible, about anything that may affect ongoing evidence generation, including:

- any substantial risk that the evidence will not be collected as planned
- new safety concerns
- the technology significantly changing in a way that affects the evidence generation process.

If data collection is expected to end later than planned, the company should contact NICE to arrange an extension to the evidence generation period. NICE reserves the

right to withdraw the guidance if data collection is delayed, or if it is unlikely to resolve the evidence gaps.

## **5 Minimum evidence standards**

There is some clinical evidence that suggests that the Online Remote Behavioural Intervention for Tics (ORBIT) technology may improve symptoms of tic disorders and Tourette syndrome in children under 12 years. The company did not report any safety concerns when using the digital technologies to support treatment of tic disorders and Tourette syndrome.

For new technologies, the committee has indicated that it may in the future be able to recommend technologies in this topic area that have evidence for:

- a beneficial impact of the digital technologies compared with standard care for treating tic disorders and Tourette syndrome without digital technologies
- a clinical improvement in tic disorders and Tourette syndrome using the Yale Global Tic Severity Rating Scale total scores
- improvements in overall patient quality of life
- resource use associated with the technologies and NHS standard care
- intervention acceptance, completion rates, patient preference, and uptake rates
- the safe use of the technology (including all adverse events).

## **6 Implementation considerations**

The following considerations around implementing the evidence generation process have been identified through working with system partners:

### **System considerations**

- There is high variation in services available to the population. The contributing services or centres should be chosen to maximise the generalisability of evidence generated. For example, by including groups of people with different socioeconomic status, or to improve data collection for any relevant subgroups. Developers should provide clear descriptions of the services and settings in which



the study is done, and the characteristics of the included children, young people and adults.

- There is an unmet need for treating tic disorders and Tourette syndrome, and access to treatment also varies across the NHS. This will bias which centres or services are selected for data collection.
- The company should provide training for staff to support use of the technology.
- The ORBIT 'e-coaches' need time for training and supervision, and to get a thorough understanding of the digital content. They also need time to support people accessing the technologies and to review their progress. Oversight of the e-coaches by more senior professionals also requires staffing time.

### **Evidence generation**

- There is an unmet need for diagnosing tic disorders and Tourette syndrome. This should be considered when assessing the inclusion criteria for future studies and is likely to lead to selection bias.
- Evidence generation should be overseen by a steering group including researchers, commissioners, healthcare professionals, and people with lived experience.
- The evidence generation process is most likely to succeed with dedicated research staff to reduce the burden on NHS staff, and by using suitable real-world data to collect information when possible.
- Careful planning of the approach to information governance is vital. The company should ensure that appropriate structures and policies are in place to ensure that data is handled in a confidential and secure manner, and to appropriate ethical and quality standards.

### **Accessibility**

- The technology may not be suitable for everyone, for example people without access to, or who cannot use, a smartphone or computer. People with cognitive impairment, problems with manual dexterity or learning disabilities may need additional help from carers or advocates.

- The digital technology could be more beneficial if it is set up to ensure that language and cultural considerations of its users are met, and the digital literacy of people using it is considered.

ISBN: [to be added at publication]